Effect of Arctium lappa L. in the dextran sulfate sodium colitis mouse model.
OBJECTIVE
To analyze the possible protective role of Arctium lappa L. (AL) in a murine model of ulcerative colitis (UC).


METHODS
BALB/c mice were administered 100 mg/kg AL powder orally each day. After 7 d, colitis was induced by administration of dextran sulfate sodium (DSS) (5% W/V) in drinking water for a further 8 consecutive days. Diarrhea and bloody stools as well as colonic histology were observed. The level of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in colonic sections were detected by immunohistochemistry.


RESULTS
There were significant differences in mean body weight values and disease activity indices between controls and AL-treated animals. Moreover, the histological findings showed that AL treatment can prevent mucosal edema, submucosal erosions, ulceration, inflammatory cell infiltration and colon damage. In addition, immunohistochemistry analysis showed that the levels of the inflammatory cytokines, IL-6 and TNF-alpha were also decreased in AL-treated groups.


CONCLUSIONS
We suggest that AL can prevent intestinal damage and decrease inflammatory cytokines in mice with DSS-induced colitis. Thus, AL could prove to be a useful food for UC.
Huang
Tzou-Chi
TC
Graduate Institute of Animal Vaccine Technology, National Pingtung University of Science and Technology, 912 Pingtung, Taiwan, China.
Tsai
Shinn-Shyong
SS
Liu
Li-Fang
LF
Liu
Yu Lin
YL
Liu
Hung-Jen
HJ
Chuang
Kuo Pin
KP
D000284:Administration, Oral; D000818:Animals; D031170:Arctium; D003093:Colitis, Ulcerative / Q000139:chemically induced* / Q000188:drug therapy* / Q000378:metabolism; D003106:Colon / Q000378:metabolism; D016264:Dextran Sulfate / Q000009:adverse effects*; D004195:Disease Models, Animal; D004487:Edema / Q000517:prevention & control; D015850:Interleukin-6 / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D008517:Phytotherapy; D028321:Plant Preparations / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D014456:Ulcer / Q000517:prevention & control; D015431:Weight Loss / Q000187:drug effects
D015850:Interleukin-6; D028321:Plant Preparations; D014409:Tumor Necrosis Factor-alpha; D016264:Dextran Sulfate
Gut. 1996 Aug;39(2):234-41
8991862
J Nutr Biochem. 2010 Jun;21(6):468-75
19428234
Br J Nutr. 2005 Apr;93 Suppl 1:S35-40
15877893
BMC Gastroenterol. 2006 Oct 28;6:31
17069659
Neth J Med. 1997 Feb;50(2):S12-4
9050327
Nat Protoc. 2007;2(3):541-6
17406617
Nature. 2007 Jul 26;448(7152):427-34
17653185
PLoS One. 2009;4(2):e4562
19234608
Gut. 1995 May;36(5):737-42
7797124
Exp Biol Med (Maywood). 2008 Nov;233(11):1469-77
18703753
Am J Chin Med. 1996;24(2):127-37
8874669
Immunopharmacol Immunotoxicol. 2002 Feb;24(1):113-9
12022439
Int Immunopharmacol. 2009 Aug;9(9):1042-8
19393773
Clin Gastroenterol Hepatol. 2008 Oct;6(10):1112-6
18928936
Biochem Biophys Res Commun. 2005 Nov 18;337(2):647-54
16202978
Gastroenterology. 2008 Feb;134(2):577-94
18242222
Mem Inst Oswaldo Cruz. 2002 Oct;97(7):1027-31
12471432
J Pharm Pharmacol. 2008 Jun;60(6):795-801
18498717
Am J Gastroenterol. 2001 May;96(5):1486-93
11374687
J Dent Res. 1995 Jul;74(7):1367-73
7560387
Biosci Biotechnol Biochem. 1993 Sep;57(9):1591-2
7764226
Pediatr Clin North Am. 1996 Apr;43(2):451-70
8614610